Article Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination
|
|
- Anabel Harvey
- 5 years ago
- Views:
Transcription
1 RBMOnline - Vol 13. No Reproductive BioMedicine Online; on web 30 May 2006 Article Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination Dr Jamal was born in Lebanon and received his MD degree from the University of Istanbul in He completed his residency training in obstetrics and gynaecology there in 2001 and a fellowship in reproductive endocrinology and infertility in After completing his fellowship, Dr Jamal spent 2 years as a member of the medical staff at Eurofertil Reproductive Health Centre before moving to the Antalya IVF Center. His research interests include areas of assisted reproductive technologies, infertility and reproductive surgery. Dr Hashim Jamal Aynur Baysoy 1, Hasan Serdaroglu 1, Hashim Jamal 2,3, Emre Karatekeli 2, Hakan Ozornek 2, Erkut Attar 1 1 Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Istanbul University, Faculty of Medicine, Istanbul, Turkey 2 Eurofertil Reproductive Health Centre, Istanbul, Turkey 3 Correspondence: hashimjamal@hotmail.com Abstract This pilot study was conducted to compare the results of intrauterine insemination (IUI) under ovarian stimulation with either letrozole (Femara) or human menopausal gonadotrophin (HMG). A randomized controlled trial was conducted. Eighty women aged years with unexplained infertility of at least 2 years duration were randomized according to a computergenerated randomization list into the letrozole group and the HMG group. Letrozole was administered at 5 mg/day from day 3 to day 7 of the IUI cycle. HMG injections were started on day 3 at a dose of 75 IU for women under 30 years old and 150 IU for women over 30 years old and monitored periodically by vaginal ultrasound and oestradiol concentrations. The variables selected for analysis were clinical pregnancy rate, endometrial thickness, length of follicular phase and number of preovulatory follicles. No statistically significant difference in clinical pregnancy rates per cycle was found for patients in the letrozole or HMG group (18.4 versus 15.7%). Cost was significantly higher in the HMG stimulation cases (P < 0.001) and no injections were required in the letrozole group. In conclusion, letrozole offers a new treatment regimen in ovarian stimulation regimens for IUI that is cost effective, simple and convenient for the patients. Keywords: HMG, intrauterine insemination, aromatase inhibitors 208 Introduction Unexplained infertility affects 15% of couples presenting with infertility (Aboulghar et al., 2003). Proposed treatment regimens include ovulation induction with oral or injectable medications, combinations of intrauterine insemination (IUI) with ovulation induction, and assisted reproductive technologies. Ovulation induction combined with IUI is one of the oldest treatments for unexplained infertility, and couples with unexplained infertility should first be exposed to ovulation induction with IUI and be offered IVF only after the failure of these therapies (Homburg and Insler, 2002). Over the years, ovulation has been stimulated by the oral medication clomiphene citrate or injectable gonadotrophin treatment (human menopausal gonadotrophin; HMG or recombinant FSH) combined with intercourse or IUI. There have been relatively few alternatives for the treatment of infertile couples. The reported pregnancy rates per cycle of IUI in conjunction with ovulation induction have usually varied between 8 and 22% (Sunde et al., 1988; Dodson and Hane, 1991; Cohlen et al., 1998). Letrozole (Femara) is one of a new class of drugs known as aromatase inhibitors, which act by inhibiting aromatase activity and thereby suppressing systemic production of oestrone from androstenedione. Aromatase inhibitors have become an important part of ovulation induction protocols for the treatment of infertility (Vladimirov, 2004). Letrozole is a new orally active, potent and selective aromatase inhibitor first approved
2 for the hormonal treatment of advanced breast cancer in postmenopausal women (Roseman et al., 1997). Studies have shown that aromatase inhibitors are a successful method of inducing and augmenting ovulation (Metwally and Caspar, 2001). Aromatase inhibitors are also effective in the medical treatment of endometriosis (Fatemi et al., 2005). The evaluation of data from recent clinical trials has shown that transient inhibition of aromatase activity in the early follicular phase with the aromatase inhibitor letrozole results in stimulation of ovarian folliculogenesis similar to that seen with clomiphene citrate, with no apparent adverse effect on endometrial thickness or pattern at mid-cycle (Fisher et al., 2002). Both pregnancy rate and endometrial thickness were comparable when patients were co-treated with gonadotrophin and letrozole in order to reduce the FSH dosage required for ovarian stimulation (Healey et al., 2003). Another observed effect of aromatase inhibitors is a decrease in oestradiol production, with approximately a 50% diminution in oestradiol/mature follicles in peripheral blood on the day of human chorionic gonadotrophin (HCG) administration (Metwally and Caspar, 2001, 2002, 2003). As LH surge is induced by a late follicular rise in oestradiol concentrations that feeds back positively on the hypothalamo pituitary axis (Hoff, 1983), it is anticipated that letrozole delays the rise in LH. Letrozole not only lowers oestradiol but also the follicular protein(s) that antagonize(s) the LH surge (Metwally and Caspar, 2003). The primary objective of this pilot study was to assess pregnancy rate when using letrozole in IUI cycles, and whether it would be worthwhile to consider letrozole for clomiphene failures before going on to gonadotrophin treatment. The study was also designed to test the effects of the aromatase inhibitor letrozole on endometrial thickness, follicular phase length and premature luteinization compared with HMG treatment cycles. Materials and methods A total of 80 couples undergoing ovarian stimulation and IUI cycles were enrolled in this pilot study. The study was initiated to assess the usefulness of letrozole (a treatment of which the authors had no previous experience) in comparison with the treatment that was in use in the authors department. The sample size needed to detect a significant difference in pregnancy rates was not calculated. As the number of patients enrolled was small, the study was defined as a pilot study. All patients diagnosed as having unexplained infertility (lack of conception after at least 2 years of regular unprotected intercourse) had regular menstrual cycles of days duration, a pelvic ultrasound showing uterus and ovaries of normal size and structure, a hysterosalpingogram and/ or laparoscopy demonstrating tubal patency, thyroid and reproductive hormones within the normal range. The luteal progesterone concentrations were not measured. Semen analysis was performed at least twice with an interval of 3 months between tests and was acceptable according to the guidelines of the World Health Organization (WHO, 1999). All women in both groups had previously undergone at least one ovulation induction treatment cycle combined with intercourse but this was their first IUI cycle. The washout period between previous ovulation inductions and current treatments was not checked, there was no significant difference between the two groups in terms of previous ovulation induction treatments, and the average number of failed cycles in each group before moving on to IUI was 3 4 cycles. This pilot study was approved by the Ethics Committee of the hospital (Istanbul University, Faculty of Medicine). All couples were randomly assigned to one of two treatment groups according to a computer-generated randomization list. Only the specialist who had performed the IUI was blinded to group assignment. Patients were aware of the treatment allocation. Over the typical range of patient ages, letrozole dosage does not change, but the standard HMG protocol assigns a higher dosage to older patients. The intention was to compare letrozole with the standard HMG protocol. On day 3 of the treatment cycle, a baseline transvaginal ultrasound scan was performed. All sonograms were carried out by the same physician who performed the IUI. The endometrial stripe was measured at its maximum anteroposterior thickness along the longitudinal axis of the uterine body. When there was no ovarian cyst on the scan, in group A (letrozole, n = 40) stimulation began on day 3 with the administration of, 5 mg/day of letozole (Femara; Novartis Pharma AG, Switzerland) from day 3 to day 7 of the menstrual cycle. In group B (HMG, n = 40), 75 IU (<30 years) and 150 IU ( 30 years) of HMG (Menogon; Ferring, Germany) were given i.m. daily from day 3 onwards for 5 days. After this, the dose and duration of HMG treatment were adjusted during the monitoring of the follicular development according to the patient s response including the number of growing follicles and oestradiol concentrations. After day 7 of the menstrual cycle, all patients were evaluated every other day by transvaginal ultrasound and measurement of oestradiol and LH blood concentrations. To determine LH and oestradiol, a commercially available immunometric assay kit (Elecsys; Roche Diagnostics GmbH Mannheim, Germany) was used. HCG 10,000 IU (Pregnyl; Organon, Turkey) was given when the leading follicle was 17 mm in diameter. A single IUI was performed h after HCG administration if no endogenous LH surge occurred. An LH surge was defined as an increase in LH concentration 100% over the mean of the preceding 2 days (Metwally and Caspar, 2003). When LH surge occurred, insemination was performed on the following day, but that cycle was not taken into consideration. IUI was performed using an intrauterine catheter (Embryon EDL; Rocketmedical, UK) with a 1-ml syringe. The catheter was gently passed through the cervical canal and the sperm suspension expelled into the uterine cavity. Insemination volumes ranged from 0.5 to 1 ml. No luteal support was given. The patient was asked to rest in a supine position for 15 min after IUI and thereafter to resume her routine activities. IUI was performed by the same physician for all patients. If menstruation was delayed after IUI, transvaginal ultrasonography was performed 3 weeks later. Only clinical 209
3 pregnancies (viable fetus) that were diagnosed by transvaginal ultrasonography were considered in the current analysis. The variables selected for analysis were pregnancy rate, thickness of the endometrium, length of the follicular phase, premature LH surge frequency, number of pre-ovulatory follicles ( 14 mm in diameter) and complications of the two study protocols. Comparison between variables was performed by the Student s t-test, chi-squared test and Fisher s exact test. The sample size of 40 cases and 40 controls at probability = 0.05 has statistical power of about 6%. The power of the study was low, P < 0.05 being considered statistically significant. P-values for all other outcomes can be affected by multiple comparisons and are given only for context. Results A total of 80 patients (40 in each treatment group) were recruited to this pilot study. All the patients treated had primary infertility. The letrozole group (group 1) and the HMG group (group 2) were comparable with regard to demographic traits: age, mean basic diagnostic parameters and cause and duration of infertility (Table 1). Physical examination, hormone profiles, ultrasonography, semen analysis and hysterosalpingography were all normal in the two groups (Table 1). Comparison of the clinical results obtained in the two groups is given in Table 2. Pregnancy rates were not significantly different between the two groups. There were pregnancies in seven of the 38 letrozole IUI cycles (18.42%) and in six of the 38 HMG IUI cycles (15.78%). The number of follicles measuring 14 mm on the day of HCG administration was lower in the letrozole than in the HMG group (1.79 ± 1.3 and 3.21 ± 1.6 respectively). Also in the HMG group, the oestradiol concentrations on the day of HCG administration were considerably higher than those of the letrozole group ( ± 368 and ± 80 respectively). Although increased thickness of the endometrium was observed in the HMG group, there was no difference in endometrial pattern between the two groups. The triple-line endometrial pattern was found to be 92.10% in group A and 94.73% in group B. The 95% confidence intervals overlapped for the percentages with triple line appearance. When the length of the follicular phase in the patients receiving letrozole was compared with the follicular length in the HMG patients, there was a shortening among the HMG group. The length of stimulation was longer in the letrozole group (12.77 ± 1.9 versus ± 1.7 days). The mean dose of HMG (mean number of ampoules/cycle) was 15.5 ampoules/cycle. The dosage of letrozole was stable at 5 mg/day, 10 tablets/cycle. Letrozole cost US$43 per cycle, while HMG was more expensive at US$225 per cycle. LH concentrations were determined in peripheral blood on day 3 of the treatment cycles, then 5 days later and then every other day until HCG administration. The difference between the two groups was not statistically significant. There were four premature luteinizations (two in each group). In this pilot study, there was only one case of moderate ovarian hyperstimulation syndrome (OHSS) in the HMG group; for this case outpatient care was sufficient. There were two multiple pregnancies, one triplet in the letrozole group and one twin in the HMG group. Table 1. Comparison of demographic data and baseline hormonal parameters of the patients receiving letrozole (group A) or gonadotrophin (group B). Patient parameter Letrozole Gonadotrophin (group A) (group B) Age (years) ± ± 4.3 Duration of infertility (years) 5.31 ± ± 3.2 Day 3 FSH (IU/l) 6.41 ± ± 1.7 Day 3 LH (IU/l) 5.81 ± ± 2.1 Day 3 oestradiol (pg/ml) ± ± 13.4 Semen parameters before preparation for insemination Age of male partner (years) ± ± 5.9 Sperm count (10 6 /ml) 61 ± 17 (21 270) 63 ± 23 (23 189) Motile spermatozoa (%) 52 ± 11 (40 87) 56 ± 13 (42 69) Normal sperm forms (%) 42 ± 11 (33 67) 46 ± 12 (30 61) 210 Values are means ± SD; values in parenthesis are ranges.
4 Table 2. Comparison of the clinical results obtained in patients receiving letrozole (group A) or gonadotrophin (group B). Parameter Letrozole Gonadotrophin P-value (group A) (group B) Follicular phase (days) ± ± Follicle number (n) 1.79 ± ± 1.6 <0.001 Endometrial thickness (mm) 8.91 ± ± Trilaminar pattern (%) NS HCG day of oestradiol (pg/ml) ± ± 368 <0.001 Premature luteinization (n) 2 2 NS Pregnancy rate (%) 7/38 (18.42) 6/38 (15.78) NS Cost (US$) <0.001 Multiple gestation (n) 1 (triplet) 1 (twin) NS OHSS (n) 1 moderate NS Values are means ± SD. NS = difference not statistically significant. Discussion There are currently several hormonal treatment protocols for ovarian stimulation combined with IUI, but the optimal, most cost-effective method has not yet been determined. The use of gonadotrophins alone for ovarian stimulation is an established protocol in IUI treatment (Plosker et al., 1994). The average cycle fecundity range, according to the results of studies that have included women with various infertility aetiologies, is from 9 to 20% (Aboulghar et al., 1993). The expected baseline pregnancy rate with active control HMG in the authors department is 15 20% per cycle. Both gonadotrophins, HMG and recombinant FSH, yielded comparable results (Van Wely, 2003). In some studies, HMG administration was associated with lower treatment duration, gonadotrophin dose, cost, and clinical outcome compared with recombinant FSH-α (Filicori et al., 2003). The drawbacks of the gonadotrophins are their high cost (both for the medication and the extensive monitoring required), inconvenience, risk of high-order multiple gestations and perhaps most importantly, risk of the potentially life-threatening OHSS (Olivennes, 2003). The new generation aromatase inhibitor letrozole is now used in ovulation induction and in many infertility situations (Metwally and Caspar, 2001; Healey et al., 2003). Letrozole has been shown to improve outcome in IUI cycles combining injectable FSH with oral ovulation induction (Metwally and Caspar, 2004). Recent studies report that the combination of letrozole and FSH enhances follicular recruitment while reducing the amount of FSH needed for optimal stimulation, ultimately reducing the cost of the cycle (Metwally and Caspar, 2003, 2004). The use of aromatase inhibitors during assisted reproduction reduces the FSH dose needed to achieve optimum ovarian stimulation, improves ovarian response to FSH in poor responders, terminates the positive feedback loop and improves ovarian response to ovarian stimulation in infertile cases, improves implantation rates in assisted reproduction technology, and reduces oestrogen concentrations to diminish the risk of OHSS during ovarian stimulation (Fatemi et al., 2003; Vladimirov, 2004). Although low oestradiol concentrations and small numbers of mature follicles were obtained at the time of the LH surge in the letrozole group, pregnancy rate was highest in the letrozole group. It is difficult to draw definitive conclusions from the present data regarding pregnancy rates, but it can be said that a very good outcome in terms of achievement of pregnancy was obtained in the letrozole group. Another outcome noted was that the stimulation time (from day 3 of the menstrual cycle until at least one follicle reached 17 mm in diameter) lasted longer and the LH surge triggered later in the letrozole group than the HMG group. As other authors (Metwally and Caspar, 2003) have stated before, this longer time of stimulation may have beneficial effects on oocyte maturation and oocyte quality, which may be a reason why more pregnancies occurred in the letrozole group. In a comparison study in 2002 between letrozole and clomiphene, women who took letrozole had lower oestrogen concentrations than those taking clomiphene (Fisher, 2002). In the present study, despite significantly lower (P < 0.001) oestradiol concentrations in letrozole-treated women, endometrial development was unaffected, and endometrial thickness and pattern were acceptable in both groups. Letrozole has a very short half-life (~45 h), and is therefore quickly cleared from the body. For this reason, it is less likely to adversely affect the endometrium and cervical mucus (Metwally and Caspar, 2001; Cortinez et al., 2005). Serious complications (OHSS, multiple pregnancy) were rare in the two groups. Low oestradiol concentrations and small numbers of mature follicles at the time of the LH surge in the letrozole group may be a way to minimize and thereby avoid the complications of OHSS and multiple pregnancy. However, 211
5 212 to compare such an outcome, a large study including a very large number of patients would be required. The results support the efficacy of letrozole. A very acceptable clinical pregnancy rate was obtained and no injection was required with letrozole. Overall, ovarian stimulation with letrozole is cost effective, simpler and more convenient than HMG. References Aboulghar M, Mansour R, Serour G, Al-Inany H 2003 Diagnosis and management of unexplained infertility: an update. Archives of Gynecology and Obstetrics 267, Aboulghar M, Mansour R, Serour G et al Ovarian superstimulation and intrauterine insemination for the treatment of unexplained infertility. Fertility and Sterility 60, Cohlen B, te Velde E, van Kooij R et al Controlled ovarian hyperstimulation and intrauterine insemination for treating male subfertility: a controlled study. Human Reproduction 13, Cortinez A, De Carvalho I, Vantman D et al Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients. Fertility and Sterility 83, Dodson W, Haney A 1991 Controlled ovarian hyperstimulation and intrauterine insemination for treatment of infertility. Fertility and Sterility 55, Fatemi HM, Al-Turki HA, Papanikolaou EG et al Successful treatment of an aggressive recurrent post-menopausal endometriosis with an aromatase inhibitor. Reproductive BioMedicine Online 11, Fatemi H, Kolibianakis E, Tournaye H et al Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reproductive BioMedicine Online 7, Filicori M, Cognigni G, Pocognoli P et al Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. Fertility and Sterility 80, Fisher S, Reid R, Van Vugt D, Casper R 2002 A randomized doubleblind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertility and Sterility 78, Healey S, Tan S, Tulandi T, Biljan M 2003 Effects of letrozole on superovulation with gonadotropins in women undergoing intrauterine insemination. Fertility and Sterility 80, Homburg R, Insler V 2002 Ovulation induction in perspective. Human Reproduction Update 8, Metwally M, Casper R 2004 Aromatase inhibition reduces the dose of gonadotropin required for controlled ovarian hyperstimulation. Journal of the Society for Gynecologic Investigation 11, Metwally M, Casper R 2003 Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Human Reproduction, Metwally M, Casper R 2002 Aromatase inhibition improves ovarian response to follicle-stimulating hormone in poor responders. Fertility and Sterility 77, Metwally M, Casper R 2001 Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertility and Sterility 75, Olivennes F 2003 Patient-friendly ovarian stimulation. Reproductive BioMedicine Online 7, Plosker S, Jacobson W, Amato P 1994 Predicting and optimizing success in an intra-uterine insemination programme. Human Reproduction 9, Roseman B, Buzdar A, Singletary S 1997 Use of aromatase inhibitors in postmenopausal women with advanced breast cancer. Journal of Surgical Oncology 66, Sunde A, Kahn J, Molne K 1998 Intrauterine insemination: a European collaborative report. Human Reproduction 3, Van Wely M 2003 Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database System Reviews 1, CD Vladimirov I 2004 Aromatase inhibitors is it a new opportunity in the treatment of infertility? Akusherstvo i Ginekologiia 43, World Health Organization 1999 WHO Laboratory Manual for the Examination of the Human Semen and Sperm Cervical Mucus Interaction, 4th edn. Cambridge University Press, Cambridge, UK. Paper based on contribution presented at the 21st Meeting of the European Society of Human Reproduction and Embryology (ESHRE 2005), Denmark. Received 13 March 2006; refereed 29 March 2006; accepted 8 May 2006.
Setting The setting was secondary care. The economic study was carried out in Turkey.
Letrozole versus human menopausal gonadotrophin in women undergoing intrauterine insemination Baysoy A, Serdaroglu H, Jamal H, Karatekeli E, Ozornek H, Attar E Record Status This is a critical abstract
More informationOriginal Article. Fauzia HaqNawaz 1*, Saadia Virk 2, Tasleem Qadir 3, Saadia Imam 3, Javed Rizvi 2
Original Article Comparison of Letrozole and Clomiphene Citrate Efficacy along with Gonadotrophins in Controlled Ovarian Hyperstimulation for Intrauterine Insemination Cycles Fauzia HaqNawaz 1*, Saadia
More informationInfertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary
Subfertility Infertility: failure to conceive within one year of unprotected regular sexual intercourse. Primary secondary Infertility affects about 15 % of couples. age of the female. Other factors that
More informationArticle Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study
RBMOnline - Vol 13. No 2. 2006 166-172 Reproductive BioMedicine Online; www.rbmonline.com/article/2261 on web 19 May 2006 Article Aromatase inhibitors in ovarian stimulation for IVF/ICSI: a pilot study
More informationNeil Goodman, MD, FACE
Initial Workup of Infertile Couple: Female Neil Goodman, MD, FACE Professor of Medicine Voluntary Faculty University of Miami Miller School of Medicine Scope of Infertility in the United States Affects
More informationLetrozole versus Clomiphene Citrate in Patients with Anovulatory Infertility
South Asian Letrozole Federation versus of Clomiphene Obstetrics Citrate and Gynecology, in Patients with January-April Anovulatory Infertility 2009;1(1):19-23 ORIGINAL STUDIES Letrozole versus Clomiphene
More informationLow Dose hmg As a First choice for Ovarian Stimulation in IUI cycles
Low Dose hmg As a First choice for Ovarian Stimulation in IUI cycles aslan, M.D Department of Obstetrics & Gynecology, Cairo University Abstract Objective: to compare pregnancy rates following low dose
More informationRelation between the Number and Size of Follicles in Ovulation Induction and the Rate of Pregnancy
Relation between the Number and Size of Follicles in Ovulation Induction and the Rate of Pregnancy Aseel Mosa Jabber M.SC.G.O. The department of Obstetrics and Gynecology, Faculty of Medicine Thi-qar university
More informationComparison of the success rate of letrozole and clomiphene citrate. in women undergoing intrauterine insemination
Received: 10.2.2006 Accepted: 8.11.2006 Original Article Comparison of the success rate of letrozole and clomiphene citrate in women undergoing intrauterine insemination Robab Davar*, Maryam Asgharnia
More informationInfertility DR. RAHUL BEVARA
Infertility DR. RAHUL BEVARA Definitions Infertility is defined as the inability to conceive after one year of unprotected coitus. Affects 10-15% of couples Primary Infertility, that is inability to conceive
More informationWhich is the Best Protocol of Ovarian Stimulation Prior to Artificial Insemination by Donor
Journal of Reproduction & Contraception doi: 10.7669j.issn.1001-7844.2014.01.0041 2014 Mar.; 25(1):41-48 E-mail: randc_journal@163.com Which is the Best Protocol of Ovarian Stimulation Prior to Artificial
More informationArticle Prediction of pituitary down-regulation by evaluation of endometrial thickness in an IVF programme
RBMOnline - Vol 8. No 5. 2004 595-599 Reproductive BioMedicine Online; www.rbmonline.com/article/1065 on web 17 March 2004 Article Prediction of pituitary down-regulation by evaluation of endometrial thickness
More informationArticle Effect of cetrorelix dose on premature LH surge during ovarian stimulation
RBMOnline - Vol 16. No 6. 2008 772-777 Reproductive BioMedicine Online; www.rbmonline.com/article/3181 on web 18 April 2008 Article Effect of cetrorelix dose on premature LH surge during ovarian stimulation
More informationInfertility. Review and Update Clifford C. Hayslip MD Intrauterine Inseminations
Infertility Review and Update Clifford C. Hayslip MD Intrauterine Inseminations Beneficial effects of IUI not consistently documented in studies No deleterious effects on fertility 3-4 cycles of IUI should
More informationApproach to ovulation induction and superovulation in women with a history of infertility. Anatte E. Karmon, MD
Approach to ovulation induction and superovulation in women with a history of infertility Anatte E. Karmon, MD Disclosures- Anatte Karmon, MD No financial relationships to disclose 2 Objectives At the
More informationPrinciples of Ovarian Stimulation
Principles of Ovarian Stimulation Dr Genia Rozen Gynaecologist and Fertility Specialist Royal Women s Hospital and Melbourne IVF Learning objectives Why ovarian stimulation Recap physiology Ovarian cycle
More informationCommon protocols in intra-uterine insemination cycles
Common protocols in intra-uterine insemination cycles Doç. Dr. Candan İltemir Duvan Turgut Özal Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum AD Ovulation induction with intra-uterine insemination
More informationInfertility treatment
In the name of God Infertility treatment Treatment options The optimal treatment is one that provide an acceptable success rate, has minimal risk and is costeffective. The treatment options are: 1- Ovulation
More informationInfertility. Thomas Lloyd and Samera Dean
Infertility Thomas Lloyd and Samera Dean Infertility Definition Causes Referral criteria Assisted reproductive techniques Complications Ethics What is infertility? Woman Reproductive age Has not conceived
More informationComparative Evaluation of Sequential Regimes of Gonadotropins with Clomiphene Citrate and Letrozole for Ovulation Induction
CODEN (USA)-IJPRUR, e-issn: 2348-6465 International Journal of Pharma Research and Health Sciences Available online at www.pharmahealthsciences.net Original Article Comparative Evaluation of Sequential
More informationUnderstanding Infertility, Evaluations, and Treatment Options
Understanding Infertility, Evaluations, and Treatment Options Arlene J. Morales, M.D., F.A.C.O.G. Fertility Specialists Medical Group, Inc. What We Will Cover Introduction What is infertility? Briefly
More informationClinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin in Normogonadotropic Infertile Patients
International Reproductive Medicine Volume 2013, Article ID 135258, 4 pages http://dx.doi.org/10.1155/2013/135258 Clinical Study Clinical Effects of a Natural Extract of Urinary Human Menopausal Gonadotrophin
More informationMinimal stimulation protocol for use with intrauterine insemination in the treatment of infertility Dhaliwal L K, Sialy R K, Gopalan S, Majumdar S
Minimal stimulation protocol for use with intrauterine insemination in the treatment of infertility Dhaliwal L K, Sialy R K, Gopalan S, Majumdar S Record Status This is a critical abstract of an economic
More informationAgonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M
Agonist versus antagonist in ICSI cycles: a randomized trial and cost effectiveness analysis Badrawi A, Zaki S, Al-Inany H, Ramzy A M, Hussein M Record Status This is a critical abstract of an economic
More informationIndian Journal of Basic and Applied Medical Research; September 2015: Vol.-4, Issue- 4, P
Original article: To study post intrauterine insemination conception rate among infertile women with polyp and women with normal uterine endometrium cavity 1Dr. Archana Meena, 2 Dr. Renu Meena, 3 Dr. Kusum
More informationArticle Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist compared with natural cycles
RBMOnline - Vol 13. No 3. 2006 326 330 Reproductive BioMedicine Online; www.rbmonline.com/article/1911 on web 13 June 2006 Article Luteal hormonal profile of oocyte donors stimulated with a GnRH antagonist
More information2017 United HealthCare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1143-4 Program Prior Authorization/Notification Medication Menopur (menotropins) * P&T Approval Date 8/2014, 5/2015, 5/2016, 5/2017
More informationThe effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study
Clinical research The effect of adding oral oestradiol to progesterone as luteal phase support in ART cycles a randomized controlled study Ashraf Moini 1,2, Shahrzad Zadeh Modarress 3, Elham Amirchaghmaghi
More informationFertility assessment and assisted conception
Fertility assessment and assisted conception Dr Geetha Venkat MD FRCOG Director Pulse Learning Women s health 14 September 2016 Disclosure statement Dr Venkat is a director of Harley Street Fertility Clinic.
More informationI. ART PROCEDURES. A. In Vitro Fertilization (IVF)
DFW Fertility Associates ASSISTED REPRODUCTIVE TECHNOLOGY (ART) Welcome to DFW Fertility Associates/ Presbyterian-Harris Methodist Hospital ARTS program. This document provides an overview of treatment
More informationFemale Reproductive Physiology. Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF
Female Reproductive Physiology Dr Raelia Lew CREI, FRANZCOG, PhD, MMed, MBBS Fertility Specialist, Melbourne IVF REFERENCE Lew, R, Natural History of ovarian function including assessment of ovarian reserve
More informationK.W.Fuh, X.Wang, A.Tai, I.Wong and R.J.Norman 1
Human Reproduction vol.12 no.10 pp.2162 2166, 1997 Intrauterine insemination: effect of the temporal relationship between the luteinizing hormone surge, human chorionic gonadotrophin administration and
More informationIs the fallopian tube better than the uterus? Evidence on intrauterine insemination versus fallopian sperm perfusion
F, V & V IN OBGYN, 2010, MONOGRAPH: 36-41 Artificial insemination Is the fallopian tube better than the uterus? Evidence on intrauterine insemination versus fallopian sperm perfusion Arne SUNDE 1, Jarl
More informationClinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G.
UvA-DARE (Digital Academic Repository) Clinical consequences of ovarian stimulation in assisted conception and in PCOS Al-Inany, H.G. Link to publication Citation for published version (APA): Al-Inany,
More informationInformation Booklet. Exploring the causes of infertility and treatment options.
Information Booklet Exploring the causes of infertility and treatment options www.ptafertility.co.za info@ptafertility.co.za +27 12 998 8854 Faith is taking the first step even if you don t see the whole
More informationORIGINAL ARTICLE ENDOMETRIAL THICKNESS AND PREGNANCY OUTCOME IN IUI CYCLES
ENDOMETRIAL THICKNESS AND PREGNANCY OUTCOME IN IUI CYCLES Asha Verma 1, Rekha Mulchandani 2, Nupur Lauria 3, Kusum Verma 4, Sunita Himani 5 HOW TO CITE THIS ARTICLE: Asha Verma, Rekha Mulchandani, Nupur
More informationComparison of single versus double intra uterine insemination
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Pathak B. Int J Reprod Contracept Obstet Gynecol. 2017 Dec;6(12):5277-5281 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20175091
More informationNICE fertility guidelines. Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic
NICE fertility guidelines Hemlata Thackare MPhil MSc MRCOG Deputy Medical Director London Women s Clinic About the LWC 4 centres around the UK London Cardiff Swansea Darlington The largest sperm bank in
More information5/5/2010. Infertility FINANCIAL DISCLOSURE. Infertility Definition. Objectives. Normal Human Fertility. Normal Menstrual Cycle
Infertility FINANCIAL DISCLOSURE I HAVE NO FINANCIAL INTEREST IN ANY OF THE PRODUCTS MENTIONED IN MY PRESENTATION Bryan K. Rone, M.D. University of Kentucky Obstetrics and Gynecology I AM RECEIVING COMPENSATION
More informationComparison of tamoxifen and clomiphene citrate for induction of ovulation in cases with thin endometrium
Original Article Comparison of tamoxifen and clomiphene citrate for induction of ovulation in cases with thin endometrium Department of Obstetrics and Gynecology, Faculty of Medicine, Suez Canal University
More informationBiology of fertility control. Higher Human Biology
Biology of fertility control Higher Human Biology Learning Intention Compare fertile periods in females and males What is infertility? Infertility is the inability of a sexually active, non-contracepting
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Infertility Injectables Table of Contents Coverage Policy... 1 General Background...16 Coding/Billing Information...20 References...20 Effective Date...
More informationThe prognostic factors for pregnancy after gonadotropin-induced controlled ovarian stimulation therapy with intrauterine insemination cycles
Available online at www.medicinescience.org ORIGINAL RESEARCH Medicine Science International Medical Journal Medicine Science 2018; ( ): The prognostic factors for pregnancy after gonadotropin-induced
More informationModule 3. Infertility: Protocols and Patient Management
Module 3 Infertility: Protocols and Patient Management Ann Scalia, BSN, RN, CNOR Manager Clinical Education Specialists Mary Vietzke, BSN, RN Senior Clinical Educational Specialist Walgreens Faculty Ann
More informationJournal of American Science 2013;9(12) Mohamed Elkadi, Amr Elhelaly, Ahmed Ibrahim, Shereen Abdelaziz
Clomiphene Citrate Alone or Followed by Human Chorionic Gonadotropin In Induction of Ovulation. Mohamed Elkadi, Amr Elhelaly, Ahmed Ibrahim, Shereen Abdelaziz Department of Obstetrics and Gynecology Ain
More informationControlled Ovarian Hyperstimulation with Intrauterine Insemination Is More Successful After r-hcg Administration Than Spontaneous LH Surge
Original Article Controlled Ovarian Hyperstimulation with Intrauterine Insemination Is More Successful After r-hcg Administration Than Spontaneous LH Surge Evan Taerk, Edward Hughes, Cassandra Greenberg,
More informationControlled ovarian hyperstimulation and intrauterine insemination for treating male subfertility: a controlled study
Human Reproduction vol.13 no.6 pp.1553 1558, 1998 Controlled ovarian hyperstimulation and intrauterine insemination for treating male subfertility: a controlled study Bernard J.Cohlen 1,3, Egbert R.te
More informationArticle Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix, 3 mg) in patients undergoing assisted reproduction treatment
RBMOnline - Vol 7. No 2. 185 189 Reproductive BioMedicine Online; www.rbmonline.com/article/900 on web 18 June 2003 Article Depot GnRH agonist versus the single dose GnRH antagonist regimen (cetrorelix,
More informationClinical Study Fallopian Tube Sperm Perfusion in Treatment of Nontubal Subfertility: Is It Crucial Step prior to ART?
International Scholarly Research Network ISRN Obstetrics and Gynecology Volume 2011, Article ID 160467, 4 pages doi:10.5402/2011/160467 Clinical Study Fallopian Tube Sperm Perfusion in Treatment of Nontubal
More informationIntroduction to Intrauterine Insemination (IUI) Service
Introduction to Intrauterine Insemination (IUI) Service Assisted Reproductive Technology Unit The Chinese University of Hong Kong Prince of Wales Hospital 2017 Treatment Procedures IUI involves six main
More informationIntrauterine Insemination - FAQs Q. How Does Pregnancy Occur?
Published on: 8 Apr 2013 Intrauterine Insemination - FAQs Q. How Does Pregnancy Occur? A. The female reproductive system involves the uterus, ovaries, fallopian tubes, cervix and vagina. The female hormones,
More informationArticle Ovulation induction using low-dose step-up rfsh in Vietnamese women with polycystic ovary syndrome
RBMOnline - Vol 18. No 4. 2009 516-521 Reproductive BioMedicine Online; www.rbmonline.com/article/3636 on web 19 February 2009 Article Ovulation induction using low-dose step-up rfsh in Vietnamese women
More informationMilder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization
Milder is better? Advantages and disadvantages of "mild" ovarian stimulation for human in vitro fertilization Revelli et al. Reproductive Biology and Endocrinology 2011, 9:25 Presenter: R2 孫怡虹 Background
More informationFactors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles
ORIGINAL ARTICLE pissn 2233-8233 eissn 2233-8241 Clin Exp Reprod Med 2015;42(2):67-71 Factors influencing serum progesterone level on triggering day in stimulated in vitro fertilization cycles Ju Hee Park
More informationSubfertility & prognostic factors & intrauterine insemination
Subfertility & prognostic factors & intrauterine insemination N.Cem FIÇICIOĞLU, M.D., Ph.D. Professor and Director Department of Gynecology & Obstetrics and IVF Center Yeditepe University, School of Medicine
More informationAssisted Reproduction. By Dr. Afraa Mahjoob Al-Naddawi
Assisted Reproduction By Dr. Afraa Mahjoob Al-Naddawi Learning Objectives: By the end of this lecture, you will be able to: 1) Define assisted reproductive techniques (ART). 2) List indications for various
More informationAssisted Reproduction. Rajeevi Madankumar, 1,2 James Tsang, 1 Martin L. Lesser, 1 Daniel Kenigsberg, 1 and Steven Brenner 1 INTRODUCTION
( C 2005) DOI: 10.1007/s10815-005-4912-8 Assisted Reproduction Clomiphene citrate induced ovulation and intrauterine insemination: effect of timing of human chorionic gonadotropin injection in relation
More informationFemale Reproductive System. Lesson 10
Female Reproductive System Lesson 10 Learning Goals 1. What are the five hormones involved in the female reproductive system? 2. Understand the four phases of the menstrual cycle. Human Reproductive System
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Recombinant versus urinary follicle-stimulating hormone in intrauterine insemination cycles: a prospective, randomized analysis of cost effectiveness Gerli S, Casini M L, Unfer V, Costabile L, Bini V,
More informationDoes previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation treatment cycles?
J Assist Reprod Genet (26) 23:427 431 DOI 1.17/s1815-6-965-x ASSISTED REPRODUCTION Does previous response to clomifene citrate influence the selection of gonadotropin dosage given in subsequent superovulation
More informationCOMPARISON OF SINGLE VERSUS DOUBLE INTRAUTERINE INSEMINATION
ORIGINAL ARTICLE COMPARISON OF SINGLE VERSUS DOUBLE INTRAUTERINE INSEMINATION Kazım Gezginç*, Hüseyin Görkemli, Çetin Çelik, Rengin Karatayli, M. Nedim Çiçek, M. Cengiz Çolakoglu Department of Obstetrics
More informationDepartment of Reproduction & Infertility, Mirza Kouchak Khan Women s Hospital, Tehran University of Medical Sciences, Tehran, Iran
Global Journal of Health Science; Vol. 8, No. 4; 2016 ISSN 1916-9736 E-ISSN 1916-9744 Published by Canadian Center of Science and Education Effects of Letrozole-HMG and Clomiphene-HMG on Incidence of Luteinized
More informationIn Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome
Original Article Effect of Laparoscopic Ovarian Drilling on Outcomes of In Vitro Fertilization in Clomiphene-Resistant Women with Polycystic Ovary Syndrome Maryam Eftekhar, M.D. 1, Razieh Deghani Firoozabadi,
More informationThe Use of Gonadotropin Releasing Hormone Antagonist in Women Undergoing Intrauterine Insemination
Research Article imedpub Journals http://www.imedpub.com/ DOI: 10.21767/1989-5216.1000263 ARCHIVES OF MEDICINE The Use of Gonadotropin Releasing Hormone Antagonist in Women Undergoing Intrauterine Insemination
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 25 June 2008
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 25 June 2008 PERGOVERIS 150 IU/75 IU, powder and solvent for solution for injection B/1 glass vial - one 1 ml vial
More informationDoes triggering ovulation by 5000 IU of uhcg affect ICSI outcome? *
Middle East Fertility Society Journal Vol. 11, No. 2, 2006 Copyright Middle East Fertility Society Does triggering ovulation by 5000 IU of uhcg affect ICSI outcome? * Amany A.M. Shaltout, M.D. Mohamed
More informationPhases of the Ovarian Cycle
OVARIAN CYCLE An ovary contains many follicles, and each one contains an immature egg called an oocyte. A female is born with as many as 2 million follicles, but the number is reduced to 300,000 to 400,000
More informationSonographic determination of a possible adverse effect of domiphene citrate on endometrial growth
Human Reproduction vol.5 no.6 pp.670-674, 1990 Sonographic determination of a possible adverse effect of domiphene citrate on endometrial growth Yael Gonen 1 and Robert F.Casper Division of Reproductive
More informationComparison of the effectiveness of single intrauterine insemination (IUI) versus double IUI per cycle in infertile patients
FERTILITY AND STERILITY VOL. 80, NO. 3, SEPTEMBER 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Comparison of the effectiveness
More informationPuerto Rico Fertility Center
Puerto Rico Fertility Center General Information of the In-Vitro Fertilization Program Dr. Pedro J. Beauchamp First test-tube baby IN PUERTO RICO Dr. Pedro Beauchamp with Adlin Román in his arms. Paseo
More informationInfertility for the Primary Care Provider
Infertility for the Primary Care Provider David A. Forstein, DO FACOOG Clinical Associate Professor Obstetrics and Gynecology University of South Carolina School of Medicine Greenville Disclosure I have
More informationMenstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
Human Reproduction Vol.21, No.4 pp. 1012 1017, 2006 Advance Access publication December 8, 2005. doi:10.1093/humrep/dei415 Menstruation-free interval and ongoing pregnancy in IVF using GnRH antagonists
More informationClinical Study Comparison of IVF Outcomes between Minimal Stimulation and High-Dose Stimulation for Patients with Poor Ovarian Reserve
Hindawi Publishing Corporation International Journal of Reproductive Medicine Volume 2014, Article ID 581451, 5 pages http://dx.doi.org/10.1155/2014/581451 Clinical Study Comparison of IVF Outcomes between
More informationIntra uterine insemination (IUI) Information for Patients and Partners
Intra uterine insemination (IUI) Information for Patients and Partners What is this leaflet about and who is it for? This leaflet is produced to inform couples undergoing IUI (intrauterine insemination)
More informationF.Zayed 1 ' 3, E.A.Lenton 1 ' 2 and I.D.Cooke 2
Human Reproduction vol.12 no. 11 pp.2408-2413, 1997 Comparison between stimulated in-vitro fertilization and stimulated intrauterine insemination for the treatment of unexplained and mild male factor infertility
More informationFertility 101. About SCRC. A Primary Care Approach to Diagnosing and Treating Infertility. Definition of Infertility. Dr.
Dr. Shahin Ghadir A Primary Care Approach to Diagnosing and Treating Infertility St. Charles Bend Grand Rounds November 30, 2018 I have no conflicts of interest to disclose. + About SCRC State-of-the-art
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 22 September 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 22 September 2010 100 µg/0.5 ml, solution for injection B/1 prefilled syringe + 1 needle (CIP code: 374 590-1) 150
More informationUnexplained Infertility
Unexplained Infertility Kaylen M. Silverberg, M.D. Thomas C. Vaughn, M.D. Texas Fertility Center Austin, Texas Introduction Infertility is generally defined as the inability to conceive following one year
More informationRecent Developments in Infertility Treatment
Recent Developments in Infertility Treatment John T. Queenan Jr., MD Professor, Dept. Of Ob/Gyn University of Rochester Medical Center Rochester, NY Disclosures I don t have financial interest or other
More informationSpontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a randomized study
Reproductive BioMedicine Online (2011) 23, 484 489 www.sciencedirect.com www.rbmonline.com ARTICLE Spontaneous ovulation versus HCG triggering for timing natural-cycle frozen thawed embryo transfer: a
More informationFixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol
Yamanashi Med. J. 14(3), 77 ~ 82, 1999 Original Article Fixed Schedule for in vitro Fertilization and Embryo Transfer: Comparison of Outcome between the Short and the Long Protocol Tsuyoshi KASAI and Kazuhiko
More informationReproductive Endocrinology and Infertility Rotation Objectives. Reproductive Endocrinology and Infertility Specialists
Reproductive Endocrinology and Infertility Rotation Objectives Reproductive Endocrinology and Infertility Specialists Terry O Grady M.D., FRCSC Sarah Healey M.D., FRCSC Deanna Murphy M.D., FRCSC Sean Murphy
More informationEVALUATING THE INFERTILE PATIENT-COUPLES. Stephen Thorn, MD
EVALUATING THE INFERTILE PATIENT-COUPLES Stephen Thorn, MD Overview The field of reproductive medicine continues to evolve rapidly by offering newer diagnostic testing and therapeutic options to improve
More informationFertility Treatment: Do not be Distracted
Fertility Treatment: Do not be Distracted Fertility Treatment: do not be distracted by worthless recommendation Fertility Treatment: Do not be Distracted When contemplating options for fertility treatment
More informationRisk factors for spontaneous abortion in menotropintreated
FERTILITY AND STERILITY Copyright ~ 1987 The American Fertility Society Vol. 48, No. 4, October 1987 Printed in U.S.A. Risk factors for spontaneous abortion in menotropintreated women Michael Bohrer, M.D.*
More information08036-Barcelona, Spain. Fax: ;
RBMOnline - Vol 6. No 4. 427 431 Reproductive BioMedicine Online; www.rbmonline.com/article/859 on web 13 March 2003 Article Pregnancy after administration of high dose recombinant human LH alone to support
More informationSynchronised approach for intrauterine insemination in subfertile couples Cantineau, Astrid E. P.; Janssen, Mirjam J.; Cohlen, Ben J.
University of Groningen Synchronised approach for intrauterine insemination in subfertile couples Cantineau, Astrid E. P.; Janssen, Mirjam J.; Cohlen, Ben J. Published in: Cochrane Database of Systematic
More informationInfertility F REQUENTLY A SKED Q UESTIONS. Q: Is infertility a common problem?
Infertility (female factors). In another one third of cases, infertility is due to the man (male factors). The remaining cases are caused by a mixture of male and female factors or by unknown factors.
More informationRealizing dreams booklet.indd 1 5/20/ :26:52 AM
Realizing dreams. 18891booklet.indd 1 5/20/2010 11:26:52 AM The Journey To Parenthood The first Gator Baby was born in 1988 through the in vitro fertilization program at the University of Florida. Since
More informationIvf day 6 estradiol level
Ivf day 6 estradiol level Search It is also important to measure the estradiol on day 3. Day 2 is fine. The reason its day 3 is 15-20 years ago, the IVF medications were always started on day 3. Day 3
More informationAndrogens Hormones that are produced by the testes of the male and in small amounts by the ovaries and adrenal glands of the female.
http://www.myfertility.ca/glossary.xhtml (February 27, 2015) Glossary Acrosome This is a membrane-bound cap-like structure found at the head of the sperm. It contains enzymes that are thought to help the
More informationDecoding the effect of time interval between hcg and IUI and sperm preparation and IUI
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Agrawal S et al. Int J Reprod Contracept Obstet Gynecol. 2018 Mar;7(3):892-896 www.ijrcog.org DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20180509
More informationInfertility INA S. IRABON, MD, FPOGS, FPSRM, FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY
Infertility INA S. IRABON, MD, FPOGS, FPSRM, FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY To download lecture deck Reference Comprehensive Gynecology 7 th edition, 2017 (Lobo
More informationLUTEAL PHASE SUPPORT. Doç. Dr. Nafiye Yılmaz. Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi
LUTEAL PHASE SUPPORT Doç. Dr. Nafiye Yılmaz Zekai Tahir Burak Kadın Sağlığı Eğitim Araştırma Hastanesi TAJEV, 2014 1 ART & success *Live birth rate 2 Optimal luteal phase Etiology of luteal phase deficiency
More informationINFERTILITY: DIAGNOSIS, WORKUP AND MANAGEMENT FOR THE COMMUNITY PHYSICIAN
INFERTILITY: DIAGNOSIS, WORKUP AND MANAGEMENT FOR THE COMMUNITY PHYSICIAN Caitlin Dunne, MD, FRCSC Clinical Assistant Professor Division of Reproductive Endocrinology and Infertility Department of Obstetrics
More informationCONSENT FORM FOR TREATMENT WITH OVULATION INDUCTION MEDICATIONS AND INTRAUTERINE INSEMINATIONS
CONSENT FORM FOR TREATMENT WITH OVULATION INDUCTION MEDICATIONS AND INTRAUTERINE INSEMINATIONS INSTRUCTIONS: This consent form provides a description of the treatment that you are undertaking. Read the
More informationAge and Fertility. A Guide for Patients Revised 2012 Copyright 2012 by the American Society for Reproductive Medicine
1 Age and Fertility A Guide for Patients Revised 2012 Copyright 2012 by the American Society for Reproductive Medicine INTRODUCTION Fertility changes with age. Both males and females become fertile in
More informationOrgalutran 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1 1. NAME OF THE MEDICINAL PRODUCT 0.25 mg/0.5 ml solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each pre-filled syringe contains 0.25 mg of ganirelix (INN) in 0.5 mg aqueous solution.
More information